Market Cap 54.22M
Revenue (ttm) 10,000.00
Net Income (ttm) -4.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -41,800.00%
Debt to Equity Ratio 0.00
Volume 16,100
Avg Vol 16,394
Day's Range N/A - N/A
Shares Out 24.42M
Stochastic %K 51%
Beta -1.07
Analysts Strong Buy
Price Target $3.00

Company Profile

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Industry: Biotechnology
Sector: Healthcare
Phone: 346 355 4099
Address:
501 E. Las Olas Blvd., Suite 300, Fort Lauderdale, United States
TheRealShortSqueezy
TheRealShortSqueezy Jun. 17 at 3:44 PM
🚨 $CUE : Can Recent Milestones Fuel the Next Breakout? 📈 CUE continues to show strength, holding its rising trendline as buyers defend higher lows near key support levels. Traders are now watching to see if the stock can reclaim key resistance levels and trigger the next leg higher. Technical View: 🔹 Higher lows continue to develop 🔹 Rising trendline remains intact Key Levels to Watch: 📈 Support ➡️ $25.34 📈 Trend Support ➡️ $29.13 📈 Resistance Zone ➡️ $32.90–$34.25 📈 Breakout Trigger ➡️ $37.27 Recent company milestones include a major board transition with the addition of experienced biotech leaders Daniel Camardo and Viola Meehan, further strengthening the company's leadership team Meanwhile, the company continues advancing CUE-401 and its broader autoimmune disease pipeline, giving investors several potential catalysts to watch moving forward Communicated Disclaimer: stockresearchtoday.com/cue/ Sector Peers: $ACHV $ANIX $TCRT $INNM
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jun. 17 at 2:17 PM
🚨$CUE : Can Recent Milestones Fuel the Next Breakout? 📈 CUE continues to show strength, holding its rising trendline as buyers defend higher lows near key support levels. Traders are now watching to see if the stock can reclaim key resistance levels and trigger the next leg higher. Technical View: 🔹 Higher lows continue to develop 🔹 Rising trendline remains intact Key Levels to Watch: 📈 Support ➡️ $25.34 📈 Trend Support ➡️ $29.13 📈 Resistance Zone ➡️ $32.90–$34.25 📈 Breakout Trigger ➡️ $37.27 📈 Momentum Target ➡️ $45+ Recent company milestones include a major board transition with the addition of experienced biotech leaders Daniel Camardo and Viola Meehan, further strengthening the company's leadership team Meanwhile, the company continues advancing CUE-401 and its broader autoimmune disease pipeline, giving investors several potential catalysts to watch moving forward Communicated Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $ACHV $ANIX $TCRT
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 17 at 8:41 AM
0 · Reply
topstockalerts
topstockalerts Jun. 14 at 10:35 PM
After Hours Top Gainers PT2 $TCRT $HMR $MBAV $DXST $RECT
1 · Reply
topstockalerts
topstockalerts Jun. 13 at 12:45 AM
After Hours Top Gainers PT2 $TCRT $HMR $MBAV $DXST $RECT
0 · Reply
urban979
urban979 May. 31 at 4:35 PM
$TCRT RSI readings have ranged from about 31 to 55//
0 · Reply
mikesterz7
mikesterz7 May. 26 at 11:51 PM
$TCRT Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs. PT 5
0 · Reply
focafoca99
focafoca99 May. 26 at 6:34 PM
$TCRT shared an integrated preclinical readout for its obesity drug candidate ALN1003.
0 · Reply
StocktwitsNews
StocktwitsNews May. 26 at 6:05 PM
Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers $TCRT https://stocktwits.com/news/equity/markets/alaunos-therapeutics-tcrt-obesity-drug-study-weight-loss-liver-health-preclinical-aln1003/cZgOaMJReqA
0 · Reply
focafoca99
focafoca99 May. 26 at 3:46 PM
$TCRT released preclinical data showing ALN1003 cuts weight, improves insulin sensitivity and reduces liver fat in obese mice.
0 · Reply
Latest News on TCRT
Alaunos Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 4 weeks ago

Alaunos Therapeutics Quarterly report: Q1 2026


Valion Bio Appoints Melinda Lackey as General Counsel

May 4, 2026, 4:05 PM EDT - 6 weeks ago

Valion Bio Appoints Melinda Lackey as General Counsel

VBIO


Alaunos Therapeutics Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Alaunos Therapeutics Annual report: Q4 2025


Alaunos Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 7 months ago

Alaunos Therapeutics Quarterly report: Q3 2025


Alaunos Therapeutics Registration statement: Registration Filing

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Alaunos Therapeutics Registration statement: Registration Filing


Alaunos Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 8:00 AM EDT - 10 months ago

Alaunos Therapeutics Registration statement: Registration Filing


Alaunos Therapeutics Registration statement: Registration Filing

Aug 21, 2025, 8:00 AM EDT - 10 months ago

Alaunos Therapeutics Registration statement: Registration Filing


Alaunos Therapeutics files $50M mixed securities shelf

2025-08-21T10:10:16.000Z - 10 months ago

Alaunos Therapeutics files $50M mixed securities shelf


Alaunos Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Alaunos Therapeutics Quarterly report: Q2 2025


Alaunos Therapeutics Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Quarterly report: Q1 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

Alaunos Therapeutics Quarterly report: Q1 2025


Alaunos Therapeutics Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Annual report: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Alaunos Therapeutics Annual report: Q4 2024


Alaunos Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Alaunos Therapeutics Quarterly report: Q3 2024


Alaunos Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 6:00 PM EDT - 2 years ago

Alaunos Therapeutics Quarterly report: Q2 2024


Alaunos Therapeutics Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Quarterly report: Q1 2024


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Earnings release: Q4 2023

Apr 1, 2024, 9:30 AM EDT - 2 years ago

Alaunos Therapeutics Earnings release: Q4 2023


Alaunos Therapeutics Annual report: Q4 2023

Apr 1, 2024, 9:30 AM EDT - 2 years ago

Alaunos Therapeutics Annual report: Q4 2023


Alaunos Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 9:30 AM EST - 2 years ago

Alaunos Therapeutics Quarterly report: Q3 2023


Alaunos Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 9:30 AM EST - 2 years ago

Alaunos Therapeutics Earnings release: Q3 2023


Alaunos Therapeutics reports Q3 EPS (4c) vs (4c) last year

2023-11-14T12:35:47.000Z - 2 years ago

Alaunos Therapeutics reports Q3 EPS (4c) vs (4c) last year


Alaunos Therapeutics downgraded to Hold from Buy at Laidlaw

2023-08-15T13:51:04.000Z - 3 years ago

Alaunos Therapeutics downgraded to Hold from Buy at Laidlaw


Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c)

2023-08-14T20:46:51.000Z - 3 years ago

Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c)


Alaunos Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Quarterly report: Q2 2023


Alaunos Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Earnings release: Q2 2023


Alaunos Therapeutics Earnings Call Transcript: Q1 2023

May 10, 2023, 9:00 AM EDT - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q1 2023


Alaunos Therapeutics Quarterly report: Q1 2023

May 10, 2023, 9:00 AM EDT - 3 years ago

Alaunos Therapeutics Quarterly report: Q1 2023


Alaunos Therapeutics Earnings release: Q1 2023

May 10, 2023, 9:00 AM EDT - 3 years ago

Alaunos Therapeutics Earnings release: Q1 2023


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 14, 2023, 8:00 AM EDT - 3 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Earnings Call Transcript: Q4 2022

Mar 7, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q4 2022


Alaunos Therapeutics Annual report: Q4 2022

Mar 7, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Annual report: Q4 2022


Alaunos Therapeutics Earnings release: Q4 2022

Mar 7, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings release: Q4 2022


Alaunos Therapeutics Earnings Call Transcript: Q3 2022

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q3 2022


Alaunos Therapeutics Quarterly report: Q3 2022

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Quarterly report: Q3 2022


Alaunos Therapeutics Earnings release: Q3 2022

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings release: Q3 2022


Alaunos Therapeutics Slides: Q3 2022

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Slides: Q3 2022


Alaunos Therapeutics Earnings Call Transcript: Q2 2022

Aug 15, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Earnings Call Transcript: Q2 2022


Alaunos Therapeutics Quarterly report: Q2 2022

Aug 15, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Quarterly report: Q2 2022


Alaunos Therapeutics Earnings release: Q2 2022

Aug 15, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Earnings release: Q2 2022


CellChorus Announces Scientific Advisory Board

Jun 1, 2022, 11:39 AM EDT - 4 years ago

CellChorus Announces Scientific Advisory Board


Alaunos Therapeutics Earnings Call Transcript: Q1 2022

May 16, 2022, 8:43 AM EDT - 4 years ago

Alaunos Therapeutics Earnings Call Transcript: Q1 2022


Alaunos Therapeutics Quarterly report: Q1 2022

May 16, 2022, 8:43 AM EDT - 4 years ago

Alaunos Therapeutics Quarterly report: Q1 2022


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 27, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 27, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 15, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing


Alaunos Therapeutics Annual report: Q4 2021

Mar 30, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Annual report: Q4 2021


Ziopharm Oncology to Participate in Upcoming Conferences

May 24, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology to Participate in Upcoming Conferences


TheRealShortSqueezy
TheRealShortSqueezy Jun. 17 at 3:44 PM
🚨 $CUE : Can Recent Milestones Fuel the Next Breakout? 📈 CUE continues to show strength, holding its rising trendline as buyers defend higher lows near key support levels. Traders are now watching to see if the stock can reclaim key resistance levels and trigger the next leg higher. Technical View: 🔹 Higher lows continue to develop 🔹 Rising trendline remains intact Key Levels to Watch: 📈 Support ➡️ $25.34 📈 Trend Support ➡️ $29.13 📈 Resistance Zone ➡️ $32.90–$34.25 📈 Breakout Trigger ➡️ $37.27 Recent company milestones include a major board transition with the addition of experienced biotech leaders Daniel Camardo and Viola Meehan, further strengthening the company's leadership team Meanwhile, the company continues advancing CUE-401 and its broader autoimmune disease pipeline, giving investors several potential catalysts to watch moving forward Communicated Disclaimer: stockresearchtoday.com/cue/ Sector Peers: $ACHV $ANIX $TCRT $INNM
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jun. 17 at 2:17 PM
🚨$CUE : Can Recent Milestones Fuel the Next Breakout? 📈 CUE continues to show strength, holding its rising trendline as buyers defend higher lows near key support levels. Traders are now watching to see if the stock can reclaim key resistance levels and trigger the next leg higher. Technical View: 🔹 Higher lows continue to develop 🔹 Rising trendline remains intact Key Levels to Watch: 📈 Support ➡️ $25.34 📈 Trend Support ➡️ $29.13 📈 Resistance Zone ➡️ $32.90–$34.25 📈 Breakout Trigger ➡️ $37.27 📈 Momentum Target ➡️ $45+ Recent company milestones include a major board transition with the addition of experienced biotech leaders Daniel Camardo and Viola Meehan, further strengthening the company's leadership team Meanwhile, the company continues advancing CUE-401 and its broader autoimmune disease pipeline, giving investors several potential catalysts to watch moving forward Communicated Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $ACHV $ANIX $TCRT
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 17 at 8:41 AM
0 · Reply
topstockalerts
topstockalerts Jun. 14 at 10:35 PM
After Hours Top Gainers PT2 $TCRT $HMR $MBAV $DXST $RECT
1 · Reply
topstockalerts
topstockalerts Jun. 13 at 12:45 AM
After Hours Top Gainers PT2 $TCRT $HMR $MBAV $DXST $RECT
0 · Reply
urban979
urban979 May. 31 at 4:35 PM
$TCRT RSI readings have ranged from about 31 to 55//
0 · Reply
mikesterz7
mikesterz7 May. 26 at 11:51 PM
$TCRT Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs. PT 5
0 · Reply
focafoca99
focafoca99 May. 26 at 6:34 PM
$TCRT shared an integrated preclinical readout for its obesity drug candidate ALN1003.
0 · Reply
StocktwitsNews
StocktwitsNews May. 26 at 6:05 PM
Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers $TCRT https://stocktwits.com/news/equity/markets/alaunos-therapeutics-tcrt-obesity-drug-study-weight-loss-liver-health-preclinical-aln1003/cZgOaMJReqA
0 · Reply
focafoca99
focafoca99 May. 26 at 3:46 PM
$TCRT released preclinical data showing ALN1003 cuts weight, improves insulin sensitivity and reduces liver fat in obese mice.
0 · Reply
focafoca99
focafoca99 May. 18 at 12:26 PM
$TCRT communicated updated preclinical data on ALN1003, its oral obesity therapeutic candidate.
0 · Reply
Estimize
Estimize May. 14 at 10:00 AM
$TCRT reported - EPS and - revenue for Q1. http://www.estimize.com/intro/tcrt?chart=historical&metric_name=eps&utm_content=TCRT&utm_medium=
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 1:20 AM
$TCRT Current Stock Price: $2.55
0 · Reply
eman1200
eman1200 Apr. 30 at 4:39 PM
$TCRT has this been delisted or something?
0 · Reply
focafoca99
focafoca99 Apr. 15 at 9:13 PM
$TCRT disclosed a Nasdaq notice for failing the minimum stockholders' equity requirement and said it plans to submit a compliance plan.
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 3:01 PM
$TCRT Holding firm at these levels. Buyers keep stepping in on dips. This shows real demand.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 11 at 11:48 AM
$TCRT Current Stock Price: $2.78
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 7:14 AM
$TCRT Great piece that accurately captures TCRT's current position. So if you want to refresh your understanding of TCRT or learn about TCRT for the first time, this is essential reading. https://everyticker.com/quote/TCRT/analysis/tcrt-s-existential-gamble-a-micro-cap-biotech-bets-its-remaining-cash-on-preclinical-obesity-nasdaq-tcrt
0 · Reply
CryptoKatt
CryptoKatt Jan. 2 at 11:22 AM
$TCRT What happened to Ziopharm and captain Kirk?
0 · Reply
CloudCharm
CloudCharm Dec. 27 at 2:16 PM
$TCRT Positioning reflects caution while awaiting confirmable progress; unit economics must show steady improvement — a credible cadence of milestones would shift sentiment. The thesis tightens only when delivery matches ambition.
0 · Reply